James Kimball to Antidepressive Agents
This is a "connection" page, showing publications James Kimball has written about Antidepressive Agents.
Connection Strength
0.173
-
McCall WV, Rosenquist PB, Kimball J, Haskett R, Isenberg K, Prudic J, Lasater B, Sackeim HA. Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks. J ECT. 2011 Jun; 27(2):97-102.
Score: 0.093
-
Munger Clary HM, Croxton RD, Allan J, Lovato J, Brenes G, Snively BM, Wan M, Kimball J, Wong MH, O'Donovan CA, Conner K, Jones V, Duncan P. Who is willing to participate in research? A screening model for an anxiety and depression trial in the epilepsy clinic. Epilepsy Behav. 2020 03; 104(Pt A):106907.
Score: 0.042
-
Janicak PG, Nahas Z, Lisanby SH, Solvason HB, Sampson SM, McDonald WM, Marangell LB, Rosenquist P, McCall WV, Kimball J, O'Reardon JP, Loo C, Husain MH, Krystal A, Gilmer W, Dowd SM, Demitrack MA, Schatzberg AF. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul. 2010 Oct; 3(4):187-99.
Score: 0.022
-
Rosenquist PB, Brenes GB, Arnold EM, Kimball J, McCall WV. Health-related quality of life and the practice of electroconvulsive therapy. J ECT. 2006 03; 22(1):18-24.
Score: 0.016